Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 901-910 of 2286 for

Edit search filters
  1. Stereotactic Body Radiation Therapy with Immunotherapy for the Treatment of Mesothelioma

    Rochester, MN

  2. Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405)

    Rochester, MN

  3. A Study to Evaluate Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

    Scottsdale/Phoenix, AZ

  4. A Study of Paclitaxel with or without Cixutumumab as Second-Line Therapy for Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

    Rochester, MN

  6. A Study of the Use of Molecular Breast Imaging to Evaluate Breast Cancer Tumor Response to Therapy that is Newly Supplemental to Standard Treatment

    Rochester, MN

  7. Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

    Rochester, MN

  8. A Dose Escalation Study of HFB301001 in Adult Patients with Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

    Rochester, MN

  10. A Study to Evaluate 9-ING-41 As a Single Agent or in Combination with Ruxolitinib in Myelofibrosis Patients

    Rochester, MN

.

Mayo Clinic Footer